Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

240 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study.
Arcari A, Chiappella A, Spina M, Zanlari L, Bernuzzi P, Valenti V, Tani M, Marasca R, Cabras MG, Zambello R, Santagostino A, Ilariucci F, Carli G, Musto P, Savini P, Marino D, Ghio F, Gentile M, Cox MC, Vallisa D. Arcari A, et al. Among authors: marasca r. Leuk Lymphoma. 2016 Aug;57(8):1823-30. doi: 10.3109/10428194.2015.1106536. Epub 2015 Dec 15. Leuk Lymphoma. 2016. PMID: 26666433
Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: a multicenter Italian experience.
Vallisa D, Bernuzzi P, Arcaini L, Sacchi S, Callea V, Marasca R, Lazzaro A, Trabacchi E, Anselmi E, Arcari AL, Moroni C, Bertè R, Lazzarino M, Cavanna L. Vallisa D, et al. Among authors: marasca r. J Clin Oncol. 2005 Jan 20;23(3):468-73. doi: 10.1200/JCO.2005.06.008. J Clin Oncol. 2005. PMID: 15659492 Clinical Trial.
Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor.
Santachiara R, Maffei R, Martinelli S, Arcari A, Piacentini F, Trabacchi E, Alfieri P, Ferrari A, Leonardi G, Luppi G, Longo G, Vallisa D, Marasca R, Torelli G. Santachiara R, et al. Among authors: marasca r. Haematologica. 2008 Aug;93(8):1252-5. doi: 10.3324/haematol.12642. Epub 2008 Jun 2. Haematologica. 2008. PMID: 18519520 Free article.
Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study.
Bomben R, Dal Bo M, Capello D, Forconi F, Maffei R, Laurenti L, Rossi D, Del Principe MI, Zucchetto A, Bertoni F, Rossi FM, Bulian P, Cattarossi I, Ilariucci F, Sozzi E, Spina V, Zucca E, Degan M, Lauria F, Del Poeta G, Efremov DG, Marasca R, Gaidano G, Gattei V. Bomben R, et al. Among authors: marasca r. Br J Haematol. 2009 Feb;144(4):492-506. doi: 10.1111/j.1365-2141.2008.07469.x. Epub 2008 Nov 19. Br J Haematol. 2009. PMID: 19036101 Free article.
Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia: an Italian retrospective study.
Iannitto E, Morabito F, Mancuso S, Gentile M, Montanini A, Augello A, Bongarzoni V, D'Arco A, Di Renzo N, Fazzi R, Franco G, Marasca R, Mulè A, Musso M, Musto P, Pennese E, Piccin A, Rota-Scalabrini D, Visani G, Rigacci L. Iannitto E, et al. Among authors: marasca r. Br J Haematol. 2011 May;153(3):351-7. doi: 10.1111/j.1365-2141.2011.08597.x. Epub 2011 Mar 4. Br J Haematol. 2011. PMID: 21371003 Free article.
Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment.
Morabito F, Gentile M, Mazzone C, Rossi D, Di Raimondo F, Bringhen S, Ria R, Offidani M, Patriarca F, Nozzoli C, Petrucci MT, Benevolo G, Vincelli I, Guglielmelli T, Grasso M, Marasca R, Baldini L, Montefusco V, Musto P, Cascavilla N, Majolino I, Musolino C, Cavo M, Boccadoro M, Palumbo A. Morabito F, et al. Among authors: marasca r. Blood. 2011 Nov 24;118(22):5759-66. doi: 10.1182/blood-2011-05-353995. Epub 2011 Sep 27. Blood. 2011. PMID: 21951682 Free article. Clinical Trial.
Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial.
Cortelezzi A, Sciumè M, Liberati AM, Vincenti D, Cuneo A, Reda G, Laurenti L, Zaja F, Marasca R, Chiarenza A, Gritti G, Orsucci L, Storti S, Angelucci E, Cascavilla N, Gobbi M, Mauro FR, Morabito F, Fabris S, Piciocchi A, Vignetti M, Neri A, Rossi D, Giannarelli D, Guarini A, Foà R. Cortelezzi A, et al. Among authors: marasca r. Leukemia. 2014 Mar;28(3):642-8. doi: 10.1038/leu.2013.334. Epub 2013 Nov 13. Leukemia. 2014. PMID: 24220274 Clinical Trial.
Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile.
Mauro FR, Molica S, Laurenti L, Cortelezzi A, Carella AM, Zaja F, Chiarenza A, Angrilli F, Nobile F, Marasca R, Musolino C, Brugiatelli M, Piciocchi A, Vignetti M, Fazi P, Gentile G, De Propris MS, Della Starza I, Marinelli M, Chiaretti S, Del Giudice I, Nanni M, Albano F, Cuneo A, Guarini A, Foà R; Gruppo Italiano Malattie EMatologiche dell’Adulto Working Party for Chronic Lymphoproliferative Disorders. Mauro FR, et al. Among authors: marasca r. Leuk Res. 2014 Feb;38(2):198-203. doi: 10.1016/j.leukres.2013.11.009. Epub 2013 Nov 19. Leuk Res. 2014. PMID: 24314589 Clinical Trial.
240 results